EUVIMEDEUVIMED entdecken
Open Access

Monocyte-to-lymphocyte ratio is a prognostic predictor for patients with non-small cell lung cancer treated with stereotactic body radiation therapy

Hidekazu Tanaka, Taiki Ono, Miki Kajima, Yuki Manabe, Koya Fujimoto, Yuki Yuasa, Takehiro Shiinoki, Masayuki Matsuo

Reports of Practical Oncology and Radiotherapy · 2024

DOI: 10.5603/rpor.100168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Reports of Practical Oncology and Radiotherapy, 2024. Verfasst von Hidekazu Tanaka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The monocyte-to-lymphocyte ratio (MLR), a systemic inflammation biomarker, has been shown to predict patient outcomes in several types of cancer. This study aimed to determine the association between MLR and local control (LC) and cause-specific survival (CSS) rates in patients with non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). Materials and methods: The median age of the 194 included participants (144 men, 50 women) was 80 (range, 50–96) years. The median follow-up period was 19 (range, 1–108) months. The LC and CSS rates were calculated using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazard regression models were used to estimate the LC and CSS rates.

Results

Local recurrence was observed in 25 patients during the follow-up. Univariate Cox proportional hazards regression analysis revealed that MLR, performance status, and tumor diameter were significant factors for LC. Multivariate analysis showed MLR and tumor diameter as significant factors (p = 0.041 and 0.031, respectively). The 1- and 2-year LC rates for the lower and higher MLR groups were 97.5% and 97.5%, and 89.7% and 81.2%, respectively. During the follow-up period, 14 patients died due to NSCLC. Although MLR tended to predict CSS in univariate analysis (p = 0.086), none of the parameters was significant in predicting CSS. However, MLR as a continuous variable was a significant factor for CSS in the univariate analysis (p = 0.004).

Conclusions

Our data suggest that MLR is correlated with LC and CSS rates in NSCLC patients treated with SBRT.

Schlagwörter

Stichwörter der Autor:innen

non-small cell lung cancerstereotactic body radiation therapysystemic inflammation biomarker

Autor:innen und Institutionen

  • Department of Radiation Oncology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
  • Department of Radiology, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan.

Zitieren

APA

Tanaka, H., Ono, T., Kajima, M., Manabe, Y., Fujimoto, K., Yuasa, Y., Shiinoki, T., & Matsuo, M. (2024). Monocyte-to-lymphocyte ratio is a prognostic predictor for patients with non-small cell lung cancer treated with stereotactic body radiation therapy. Reports of Practical Oncology and Radiotherapy. https://doi.org/10.5603/rpor.100168

Vancouver

Tanaka H, Ono T, Kajima M, Manabe Y, Fujimoto K, Yuasa Y, et al. Monocyte-to-lymphocyte ratio is a prognostic predictor for patients with non-small cell lung cancer treated with stereotactic body radiation therapy. Reports of Practical Oncology and Radiotherapy. 2024. doi:10.5603/rpor.100168

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Hidekazu and Ono, Taiki and Kajima, Miki and Manabe, Yuki and Fujimoto, Koya and Yuasa, Yuki and Shiinoki, Takehiro and Matsuo, Masayuki},
  title = {Monocyte-to-lymphocyte ratio is a prognostic predictor for patients with non-small cell lung cancer treated with stereotactic body radiation therapy},
  journal = {Reports of Practical Oncology and Radiotherapy},
  year = {2024},
  doi = {10.5603/rpor.100168}
}
Kostenlos starten →